AZ Alliance Bolsters Daiichi’s US Primary Care Presence
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is moving to shore up its generic-threatened primary care business in the US through a co-promotion deal with AstraZeneca for a novel constipation drug.
You may also be interested in...
Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik
FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.